OBI Pharma’s Board of Directors approves the announcement of the Company’s 2017 individual and consolidated financial statements

1. Date of occurrence of the event: 2018/03/09
2. Company name: OBI Pharma, Inc
3. Relationship to the Company (please enter “head office” or “subsidiaries”):Parent
4. Reciprocal shareholding ratios: N/A
5. Cause of occurrence: The Company’s 2017 individual and consolidated financial statements were approved by the board of directors. Essential financial items are presented below.

From the 2017 Individual Financial Statement
Operating loss                                               :(1,188,216) KNTD
Total comprehensive loss for the period :(1,400,095) KNTD
Loss Per Share (in dollars)                          :(          8.06) NTD

From the 2017 Consolidated Financial Statement
Operating loss                                               :(1,189,642) KNTD
Total comprehensive loss for the period :(1,400,095) KNTD
Loss Per Share (in dollars)                          :(          8.06) NTD

6. Countermeasures: N/A
7. Any other matters that need to be specified: None